Validation of specific mitophagy biomarkers across Alzheimer's disease continuum

About this project

<p>The project aims to develop early diagnostic biomarkers of Alzheimer disease (AD) by validating a series of new biomarkers in serum and cerebrospinal fluid (CSF) in participants from the Czech Brain Aging Study (CBAS).This Czech–Norwegian joint project will involve researchers from CBAS - Czech team with a unique clinical cohort and a top Norwegian research team specialized in mitophagy research. We aim to:</p> <p>1.)Determine changes of designated mitophagy proteins in serum and CSF of AD individuals compared to non-AD and cognitively normal controls;</p> <p>2.)Determine the relation to demographics, cognitive status and standard AD biomarkers;</p> <p>3.)Verify the findings from CBAS on induced pluripotent stem cells and animal models;</p> <p>4.)Validate specific mitophagy proteins as early diagnostic marker of AD.</p>

Bilateral cooperation results

The bilateral collaboration leveraged complementary expertise, combining Czech clinical knowledge in Alzheimer’s disease with Oslo’s laboratory expertise in mitophagy, resulting in joint projects, student exchanges, common publications, and shared conference contributions. The partnership continues with follow-up work on sample exchanges, a detailed plan for future research presented at UiO, and a signed memorandum supporting ongoing joint grant applications and collaborative efforts.

Project partners

• University of Oslo Donor project partner· Norway